we then announce this at earnings.. Can't even imagine the spike.
going to soar again.
that is how you spell it chump, he is correct..what never heard the word??
no brainer Dr going to prescribe drug that lowers the LDL not Raises Them 45%
Amarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
"This sNDA approval of BASF as a supplier of Vascepa follows the recent sNDA approval to add Chemport, Inc. as a Vascepa API supplier and brings the number of approved Vascepa API suppliers to three. The BASF approval represents an additional step toward the goal of expanding our global supply chain to support Vascepa demand, diversify our supply base, and ensure cost-efficient supply. In addition, Amarin has plans for the submission of a fourth planned supplier in 2013
The chance of the FDA approving this 2nd indication is high in our view. This would be the first approval for this class of drug in this setting which would provide a meaningful competitive advantage to the only other approved competitor from GSK. An approval in this broader indication could rekindle discussions with potential suitors for either partnership or potential takeout. We do believe that the full potential of this news could be mitigated by the upcoming 1Q:13 earnings. Target price $13.
Wall Street 5/1/13
Leerink maintains an Outperform rating on shares.of Allergan
Some of the subjects likely to get scrutinized when Facebook (FB -1.5%) delivers its Q1 report...
check out 4/19 on chart.